UniSuper Management Pty Ltd Trims Position in Zoetis Inc. (NYSE:ZTS)

UniSuper Management Pty Ltd lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 68.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,176 shares of the company's stock after selling 68,272 shares during the quarter. UniSuper Management Pty Ltd's holdings in Zoetis were worth $5,080,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares in the last quarter. Dunhill Financial LLC lifted its stake in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis during the 4th quarter valued at $44,000. Finally, Asset Planning Inc purchased a new position in shares of Zoetis during the 4th quarter valued at $58,000. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective on the stock. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $215.90.

Remove Ads

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company's stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by company insiders.

Zoetis Stock Up 0.4 %

Shares of Zoetis stock traded up $0.70 on Wednesday, reaching $162.61. The company's stock had a trading volume of 574,550 shares, compared to its average volume of 2,592,955. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The firm's fifty day simple moving average is $166.26 and its two-hundred day simple moving average is $174.05. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $72.81 billion, a price-to-earnings ratio of 29.73, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.23%. Zoetis's payout ratio is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.